Scrip's Rough Guide To IDO
Executive Summary
IDO has emerged at the lead suitor among new cancer immunotherapy targets to partner with PD-1/L1 inhibitors; the early data help show why big pharmas are so much on board.
You may also be interested in...
NewLink CEO Reflects On Golden Age And Rapid Fall Of IDO
There is now a move back to the principle of doing randomized Phase II studies before jumping into Phase III, says CEO Chuck Link, as Roche's Genentech exits broad IDO/TDO deal.
A Wake For IDO: Bristol Ends Registrational Trials Of High-Priced Flexus Drug
Following termination of pivotal trials in three tumor types testing its in-house IDO inhibitor BMS-986205, Bristol says it is "working quickly" to assess the development of Opdivo with Incyte's epacadostat.
Scrip's Rough Guide To IL-2: Mother Of All Cytokines
Nektar Therapeutics, Alkermes and Roche are among the companies with new solutions for more safely targeting an old cytokine well validated in cancer immunotherapy. Top execs explain how and why.